Patent SG-11201900883U-A (SG)
Title: Combination treatment for hematological cancers
Inventor: HUANG FEI
IPC: A61P35/02
Filed: 2017-07-28
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIP0 I PCT onion °nolo omolom oiloo mil mu ow (10) International Publication Number WO 2018/026646 Al lmetelstat Sodium —0-- 75uM 50uM - -a- 25uM —A-- - 10uM - 5uM 0 1uM Ou M (51) International Patent Classification: A61K 31/635 (2006.01) A61P 35/00 (2006.01) A61K 31/7125 (2006.01) A61P 35/02 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/US2017/044348 (22) International Filing Date: 28 July 2017 (28.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/370,018 02 August 2016 (02.08.2016) US 16197293.0 04 November 2016 (04.11.2016) EP 62/422,738 16 November 2016 (16.11.2016) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: HUANG, Fei; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). RUSBULDT, Joshua J.; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). RIZO, Aleksandra; 920 U.S. Route 202 S, 08869 Raritan (UA). (74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jer- sey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: COMBINATION TREATMENT FOR HEMATOLOGICAL CANCERS FIG. 11 MOLM 13, 48hrs 100 90 80 70 Apoptotic Cells 60 (Double Positive) 50 40 30 20 1-1 10 0 0.01 0.1 1 10 100 1000 71' ABT-199, nM (57) : The present invention relates to a combination treatment for hematological cancers. More specifically; a combination 1-1 of a telomerase inhibitor and a Bc1-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, © the telomerase inhibitor is imetelstat or imetelstat sodium and the Bc1-2 inhibitor is ABT-199. C [Continued on next page] WO 2018/026646 Al IMEDIMOMMIDIRDERIONEEHIMINIEMOVOIMIE TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))